Clinical bottom line
Fibroblast growth factor 21 (FGF21) is an emerging metabolic regulator with promising therapeutic potential in obesity and type 2 diabetes (T2D). Its pleiotropic effects include improving insulin sensitivity, modulating lipid metabolism, and reducing hepatic steatosis. Long-acting FGF21 analogs with optimized pharmacokinetics show encouraging preclinical efficacy in nonalcoholic steatohepatitis (NASH), a common comorbidity in metabolic disorders. However, clinical translation remains in early stages, and further studies are needed to clarify optimal dosing, safety, and long-term benefits.
What the evidence shows
Yuan et al. (2019) reviewed the role of FGF21 in gestational diabetes mellitus, highlighting its involvement in glucose homeostasis and potential as a biomarker and therapeutic target in metabolic dysregulation during pregnancy.
Qi et al. (2024) demonstrated that a long-acting, site-specifically modified FGF21 analog significantly improved histological and biochemical markers of NASH in preclinical models, suggesting translational potential for treating obesity-related liver disease.
Babaknejad et al. (2018) provided a comprehensive overview of FGF21 and related fibroblast growth factors, emphasizing their roles in energy expenditure, glucose regulation, and lipid metabolism, supporting their therapeutic relevance in obesity and T2D.
Nnamani et al. (2026) explored the interaction between xenobiotic-activated pregnane X receptor and diabetes pathophysiology, indirectly implicating FGF21 pathways in metabolic regulation and potential cross-talk with nuclear receptor signaling.
Liu et al. (2022) described exercise interventions in T2D patients with abdominal obesity, noting that lifestyle modifications may synergize with FGF21-related pathways to improve metabolic outcomes.
Caveats and uncertainty
Most therapeutic data on FGF21 derive from animal or early-phase studies; robust clinical trial evidence is limited.
FGF21’s short half-life necessitates molecular modifications for sustained activity, raising concerns about immunogenicity and long-term safety.
Heterogeneity in patient populations and comorbidities may influence therapeutic response.
The complexity of FGF21 signaling networks and interactions with other metabolic regulators requires further elucidation.
How this may change practice
FGF21 analogs may become adjunctive therapies for obesity, T2D, and associated liver disease, particularly NASH, pending clinical validation.
Integration with lifestyle interventions could enhance metabolic benefits.
Monitoring of emerging clinical trial data will be essential to define patient selection and safety profiles.
Future therapies targeting FGF21 pathways might complement existing glucose-lowering and lipid-modifying agents.